These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 19216253)

  • 1. Stool test for colorectal cancer screening--it's time to move!
    Loitsch SM; Shastri Y; Stein J
    Clin Lab; 2008; 54(11-12):473-84. PubMed ID: 19216253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colon cancer screening strategies.
    Agrawal J; Syngal S
    Curr Opin Gastroenterol; 2005 Jan; 21(1):59-63. PubMed ID: 15687886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
    Quintero E
    Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New stool screening tests for colorectal cancer.
    Young GP; Cole S
    Digestion; 2007; 76(1):26-33. PubMed ID: 17947816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers.
    Karl J; Wild N; Tacke M; Andres H; Garczarek U; Rollinger W; Zolg W
    Clin Gastroenterol Hepatol; 2008 Oct; 6(10):1122-8. PubMed ID: 18928937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data].
    Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD
    Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer.
    Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD
    Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.
    Limburg PJ; Devens ME; Harrington JJ; Diehl NN; Mahoney DW; Ahlquist DA
    Am J Gastroenterol; 2003 Oct; 98(10):2299-305. PubMed ID: 14572583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colon cancer screening: which non-invasive filter tests?
    Pox C
    Dig Dis; 2011; 29 Suppl 1():56-9. PubMed ID: 22104755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method.
    Johne B; Kronborg O; Tøn HI; Kristinsson J; Fuglerud P
    Scand J Gastroenterol; 2001 Mar; 36(3):291-6. PubMed ID: 11305517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive testing for colorectal cancer: a review.
    Ouyang DL; Chen JJ; Getzenberg RH; Schoen RE
    Am J Gastroenterol; 2005 Jun; 100(6):1393-403. PubMed ID: 15929776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex differences in performance of fecal occult blood testing.
    Brenner H; Haug U; Hundt S
    Am J Gastroenterol; 2010 Nov; 105(11):2457-64. PubMed ID: 20700114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stool test for colorectal cancer screening: what is going on?
    Bonanno E; Rulli F; Galatà G; Pucci S; Sesti F; Farinon AM; Spagnoli LG
    Surg Oncol; 2007 Dec; 16 Suppl 1():S43-5. PubMed ID: 18055195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening.
    Takai T; Kanaoka S; Yoshida K; Hamaya Y; Ikuma M; Miura N; Sugimura H; Kajimura M; Hishida A
    Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1888-93. PubMed ID: 19505922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of different stool tests for the detection of cancer of the colon].
    Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
    Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fecal oncomarkers in the diagnostics of colorectal cancer].
    Mikhaĭlova EI; Pimanov SI; Voropaev EV
    Klin Med (Mosk); 2007; 85(12):62-7. PubMed ID: 18318171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance improvements of stool-based screening tests.
    van Dam L; Kuipers EJ; van Leerdam ME
    Best Pract Res Clin Gastroenterol; 2010 Aug; 24(4):479-92. PubMed ID: 20833351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.